Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ERICH3 antisense RNA 1 (ERICH3-AS1)
- Target
- ERICH3-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Non-coding RNA, Other
01
Overview
ERICH3 antisense RNA 1 (ERICH3-AS1) is a long non-coding RNA gene found on human chromosome 1. Its expression is strongly upregulated in gastric cancer tissues. Higher ERICH3-AS1 expression predicts poor prognosis, shorter disease-free survival, and earlier recurrence. While its exact mechanism is not fully understood, gene expression and pathway analyses demonstrate that high ERICH3-AS1 expression is associated with enrichment of key cancer signaling cascades (ERBB, MAPK, MTOR, p53, and Wnt) and gene products related to apoptosis (e.g., BCL2L10, CASP14), cell cycle (CDK14), and invasion/migration (MMP20, MMP26, MMP27). ERICH3-AS1 itself is not a protein nor does it encode one, making it a regulatory element rather than a classical therapeutic target; its relevance is primarily as a prognostic biomarker and as a possible modulator of tumorigenesis through control of critical cellular processes.
- Other names
- ERICH3-AS1ERICH3 antisense RNA 1
02
Biological functions
Regulation of cell cycleRegulation of apoptosisModulation of invasion and migrationPutative regulation of signaling pathways (ERBB, MAPK, MTOR, p53, Wnt, JAK-STAT)Other
03
Disease associations
Cancer (especially gastric cancer; possibly other tumors)Other (prognostic biomarker for disease-free and overall survival in cancer)
04
Biomarkers
Elevated ERICH3-AS1 expression is a potential diagnostic and prognostic biomarker for gastric cancer, indicating higher risk for early recurrence and poorer survival
Beyond the preview
Go deeper on ERICH3 antisense RNA 1 (ERICH3-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ERICH3 antisense RNA 1 (ERICH3-AS1).